Literature DB >> 2425448

Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney cell culture.

D C Rijken, D J Binnema, P Los.   

Abstract

The specific fibrinolytic properties of both high molecular weight (55 kd) and low molecular weight (30 kd) pro-urokinase from a monkey kidney cell culture were evaluated in a plasma clot lysis system and compared with those of human urokinase. The system was composed of a radiolabelled plasma clot immersed in plasma containing the fibrinolytic agent. On unit base, 55 kd pro-urokinase was approximately 1.5 times more effective in lysing the clot than 30 kd pro-urokinase and equally effective as urokinase. In contrast to urokinase, both pro-urokinase forms induced clot lysis without degrading fibrinogen in the surrounding plasma. However, a considerable activation of the fibrinolytic system in the plasma occurred as a large amount of alpha 2-antiplasmin was consumed, indicating that pro-urokinase was not fully fibrin-specific. Quenching antibodies against tissue-type plasminogen activator (t-PA) added to the plasma clot lysis system retarded but did not prevent pro-urokinase-induced clot lysis. This indicated that not only was t-PA in plasma involved in the activation of pro-urokinase (probably via plasmin), but that an additional mechanism also existed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425448     DOI: 10.1016/0049-3848(86)90112-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin.

Authors:  G A de Munk; E Groeneveld; D C Rijken
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

2.  Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney.

Authors:  A P Sappino; J Huarte; J D Vassalli; D Belin
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.